series-b
Stage
2004
Founded
1
Investors
About
RyCarma Therapeutics is a clinical-stage biotech company developing first-in-class small molecule therapeutics, known as Rycals, for cardiovascular and skeletal muscle diseases by targeting ryanodine receptor (RyR) calcium channels.
Explore RyCarma Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.